David Wetherell


Managing Partner, Biomark Capital

David Wetherell has spent 25 years as a CEO in high-tech, as well as 22 years in venture capital, the last ten have been dedicated to biotech and life sciences. From 1986 to 2006, he served as both CEO and, later, chairman of CMGI, helping build the company from $3 million to more than $1 billion in annual revenues, and creating the first venture capital firm focused on the Internet.

In 2005, he started GBP Capital, a venture capital company focused exclusively on leading edge life sciences. David has received numerous awards, including Ernst & Young’s New England Entrepreneur of the Year in 2000 and recognition as one of Money Magazine’s Top 25 investors. He earned a Bachelor of Arts in Mathematics from Ohio Wesleyan University and received an honorary doctorate from Bryant University. He sits on the board of directors for numerous companies, including HyperMed, Strand Life Sciences, and Whiteglove Health, and is Chairman at Opus Bio.

HyperMed’s new tissue oximetry device called HyperView™ is FDA 510(k) cleared.
HyperMed, HyperView, OxyVu™-1 and the company logo are trademarks of HyperMed Imaging, Inc.